Sun Pharma reports bigger-than-expected rise in Q2 profit

Sales from its U.S. formulation business rose 7.9% to 35.5 billion rupees during the quarter, while sales from its India formulations rose 11.1% to 38.43 billion rupees.

Both businesses account for 30% and 32% of total sales, respectively, Sun Pharma said.

The company's generic version of popular cancer drug Revlimid is also a significant contributor to the total sales.

Mumbai-based Sun Pharma, one of India's oldest drugmakers, which also makes popular consumer healthcare products like Revital vitamin pills and pain relief gel Volini, said its total revenue from operations rose 11.3% to 121.92 billion rupees.

The company, founded in 1983, makes generics and specialty medications for chronic and acute treatments, over-the-counter medications, anti-retrovirals and active pharmaceutical ingredients.

Rivals Dr Reddy's and Cipla last week reported better-than-expected profit on strong U.S. demand.

Read also: Sun Pharma to now offer Desidustat, first oral treatment for CKD-associated anaemia in India under brand Rytstat